Telix Pharmaceuticals’ (TLX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a research report report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock.

Several other research firms have also recently weighed in on TLX. Wedbush reissued an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Royal Bank Of Canada lowered shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Finally, Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $20.40.

Telix Pharmaceuticals Price Performance

TLX stock opened at $11.94 on Wednesday. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. The business has a 50 day moving average of $11.21 and a 200-day moving average of $9.96. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $12.48.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new position in Telix Pharmaceuticals during the second quarter worth about $975,000. Jane Street Group LLC bought a new position in Telix Pharmaceuticals in the 2nd quarter worth approximately $564,000. IHT Wealth Management LLC purchased a new position in Telix Pharmaceuticals in the 2nd quarter valued at approximately $213,000. Rhumbline Advisers raised its holdings in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares during the period. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Telix Pharmaceuticals during the third quarter worth $243,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.